



Merck & Co., Inc. Statement regarding the Martin Report

WHITEHOUSE STATION, N.J., Sept. 6, 2006 – We commend the Special Committee and Judge Martin for conducting a comprehensive, independent and objective investigation of the development and marketing of Vioxx. Throughout the entire process, we have cooperated fully with Judge Martin and his team.

After an exhaustive review, the final report confirms what we at Merck have always believed—that there is no basis for the claim that Merck knowingly put patients at risk of cardiovascular events. The report also concludes that no member of Merck’s senior management, including the senior scientists at Merck Research Labs, believed that Vioxx was prothrombotic or attempted to mislead the public. In short, Judge Martin found the Merck scientists to be highly skilled and dedicated professionals who acted in good faith.

It is to be expected that such an intense evaluation of events that took place over many years would lead to some criticisms. Some we have already addressed. For others, we will consider carefully the criticism and the facts underlying it and determine whether action is appropriate to address it.

Merck has a proud legacy of both scientific excellence and adherence to high ethical standards. We are committed to acting ethically, responsibly and, above all, with integrity.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This statement contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this statement should be evaluated together with the many uncertainties that affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

#